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The annual incidence rate of serogroup W inva-
sive meningococcal disease in the Netherlands 
increased from < 0.05/100,000 (n < 10) before 2015 
to 0.5/100,000 (n = 80) in 2017. Most isolates (94%) 
belong to clonal complex 11. The incidence rate is 
highest among  < 5 year-olds and 15–24 year-olds. The 
case fatality rate was 12% (17/138) in 2015–2017. From 
May 2018, MenACWY vaccination replaces MenC vac-
cination at age 14  months and from October 2018, 
13–14 year-olds are offered MenACWY vaccination.
The Netherlands currently experiences an ongoing 
increase of serogroup W invasive meningococcal dis-
ease (IMD). Our aim is to describe the epidemiologi-
cal and microbiological characteristics of the current 
increase and the implementation of MenACWY vaccina-
tion in the Netherlands in 2018.
Ongoing increase of serogroup W invasive 
meningococcal disease 
In the Netherlands, serogroup W IMD was very rare 
before 2015 with an average annual incidence rate of 
0.02 cases per 100,000 and on average four cases 
per year from 2010 up to 2014 (Figure 1). From 2015 
the incidence rate started to increase reaching 0.5 
per 100,000 in 2017 (n = 80). Before 2015, serogroup 
W IMD caused < 5% (18/535 for 2010–2014) of all IMD; 
this increased to 40% (80/198) in 2017. Analyses of 
the whole genome sequences of the isolates showed 
that almost all serogroup W strains from 2015 to 2017 
had the same finetype P1.5,2:F1–1 (122/134; 91%) and 
belonged to clonal complex 11 (cc11; 117/124; 94%). The 
incidence of serogroup W IMD not belonging to cc11 has 
remained stable over the last years with 1–5 cases per 
year, whereas the number of serogroup W cc11 cases 
started to increase in 2015 (Figure 1).
Figure 2  shows a cluster analysis of all available 
genome sequences of serogroup W cc11 meningococci 
isolated in 2012–2017 from Dutch patients. Isolates 
from the same year seem to cluster, i.e. the genetic 
distance between isolates is smaller within years than 
between years. Furthermore, within the same year sev-
eral separate clusters can be discerned, which may 
suggest different introductions or more likely expan-
sions of subclones. These genetic clusters were neither 
epidemiologically nor geographically associated.
In 2017, the incidence rate was highest in chil-
dren < 5  years of age (0.92/100,000; n = 8), espe-
cially those < 2  year-old (2.0/100,000; n = 7 of whom 
four cases were < 1 year-old), and 15–24  year-olds 
(0.81/100,000; n = 17) (Figure 3). The incidence rate 
was also relatively high among older adults; the inci-
dence started to increase from 45 to 50  years of age 
(0.4/100,000; n=5) up to an incidence of 1.6/100,000 
in ≥ 80 year-olds in 2017 (n = 12). From 2015 to 2017, of 
138 serogroup W IMD cases with known outcome, 17 
(12%) died; six deceased cases were 15–24  year-olds. 
In comparison, eight of 215 (4%) serogroup B IMD cases 
died from 2015 to 2017. In 2017, of 73 serogroup W IMD 
patients with known clinical manifestation, 39 (53%) 
had septicaemia, 11 (15%) had meningitis, six (8%) 
had both septicaemia and meningitis, nine (12%) had 
pneumonia, and eight (11%) had other manifestations, 
including one case with necrotising fasciitis (case 
report in [1]). Meningitis, with or without septicaemia, 
was most prevalent in < 5 year-olds and 5–14 year-olds, 
while septicaemia was most prevalent in other age 
groups.
Implementation of MenACWY vaccination 
Based on advice from an expert meeting, the Dutch 
minister of Health decided in September 2017 to start 
implementing quadrivalent conjugate meningococcal 
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vaccination (MenACWY) to control the increase in 
serogroup W IMD in the Netherlands. From May 2018 
onwards, the MenC conjugate vaccine given at 14 
months of age will be replaced by a MenACWY conju-
gate vaccine to give direct protection to this vulnerable 
age.
In addition, from October 2018 onwards, 13–14  year-
olds will be offered a MenACWY vaccination. The aim 
is to give direct protection to this age group as the 
incidence and case fatality rate of serogroup W IMD is 
high in this group. Furthermore, as meningococcal car-
riage starts to increase from the age of 14 years [2], the 
expectation is that, by targeting this age group, carriage 
and transmission of serogroup W meningococci will be 
reduced and therefore disease in other age groups, 
e.g. children < 14  months of age and older adults, will 
be reduced as well. The epidemiological situation is 
continuously monitored to assess whether additional 
measures, e.g. extension to other age groups, need to 
be taken. All eligible children will receive a personal 
invitation for MenACWY vaccination – the invitation 
for 14-months-old children will be sent to their parents 
or guardians – from the National Institute for Public 
Health and the Environment. The adolescent vaccina-
tion will be administered by the Youth Health Care of 
the Municipal Health Service at dedicated group ses-
sions. Adolescents who do not get their vaccination will 
receive a reminder within several weeks. Vaccination 
uptake will be closely monitored. Qualitative and quan-
titative research will be performed to evaluate accept-
ance of MenACWY vaccination in adolescents and their 
parents before and after introduction of vaccination.
Discussion
Previous genomic analyses have shown that the sero-
group W cc11 strain that is causing the current increase 
of IMD in the Netherlands, emerged in Brazil in 2003 
and then spread to Argentina and Chile [3]. The strain 
emerged in the United Kingdom (UK) in 2009 caus-
ing an increase of serogroup W IMD in the UK and a 
further descendent of this strain, the so-called 2013 
strain, expanded in the UK since 2013 [4,5]. The origi-
nal and 2013 UK strains emerged in the Netherlands in 
2012 and 2013, respectively, and the 2013 UK strain is 
currently causing the ongoing increase in serogroup 
W IMD [6]. Since 2015, also other European countries 
experience an increase in serogroup W IMD due to this 
specific cc11 strain including Denmark, France, Spain 
and Sweden [5,7–9], although the magnitude of the 
increase currently seems highest in the UK and the 
Netherlands. However, other countries may also see 
a further increase, and public health actions including 
vaccination could be considered.
Characteristics that seem typical for the current sero-
group W IMD increase in Europe are the age distribu-
tion, with not only a high incidence in young children 
and adolescents but also in older adults, the high case 
fatality rate compared with other serogroups, and the 
clinical manifestation, with more septicaemia, less 
meningitis and more atypical manifestations includ-
ing pneumonia and arthritis [4,6,8]. The UK reported 
a case series of teenagers with serogroup W IMD who 
presented with gastrointestinal symptoms and showed 
high case fatality rates [10]. A recent study of almost 
12,000 IMD cases from 1991–2016 in France showed a 
higher case fatality rate in IMD patients with abdomi-
nal presentations compared to all IMD patients (24% 
vs. 10%). Serogroup W, and specifically cc11, was sig-
nificantly more often the cause of IMD in patients with 
abdominal presentations [11].
Because of the ongoing increase of serogroup W IMD, 
the UK replaced the adolescent MenC conjugate vac-
cine for 13–14  year-olds and new university entrants 
by a MenACWY vaccine in the autumn of 2015 [12]. In 
addition, catch-up campaigns were implemented to 
offer the MenACWY vaccine to all 13–18 year-olds dur-
ing 2015 to 2017. First results of the programme among 
school leavers showed a 69% decrease in observed 
cases (n = 6) compared with predicted cases by trend 
analysis (n = 19.4), despite only 36.6% coverage among 
persons who left school in 2015 [13]. Early estimated 
vaccine effectiveness using the screening method was 
100% (95% confidence interval (CI): − 47 to 100%). 
Three other European countries, Austria, Greece and 
Italy, offer MenACWY vaccination to adolescents as 
part of their national vaccination programme, but not 
for reason of an increase in serogroup W IMD.
In contrast to the UK, only a single birth cohort of ado-
lescents will be offered MenACWY vaccination in the 
Netherlands. Without a catch up campaign it will take 
several years before herd protection will be achieved. 
The goal of the current implementation of MenACWY 
vaccination is therefore not to control the increase of 
serogroup W IMD immediately but to prevent higher 
number of cases in the future.
A positive additional effect of introducing MenACWY 
vaccination is that adolescents will be boosted against 
serogroup C meningococci. From sero-epidemiological 
Figure 1
Number of cases of serogroup W invasive meningococcal 
disease by clonal complex in the Netherlands, 2010–2017 
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Figure 2
Neighbour-net phylogenetic network analysis of all available genomes of serogroup W clonal complex 11 isolates from the 
Netherlands, 2012–2017 (n = 121)
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Colours represent the years when the isolates were obtained. Genomes were compared using the PubMLST genome comparator tool using 
core genome multilocus sequence typing (cgMLST v1.0) [15]. The resulting distance matrices were visualised with SplitsTree4 version 4.13.1 
[16].
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studies, it is estimated that the percentage of ado-
lescents that currently has protective antibody levels 
against serogroup C meningococci is very low in the 
Netherlands [14]. The introduction of the MenACWY 
booster in adolescents will ensure high antibody levels 
in this age group, which is necessary to maintain herd 
protection against serogroup C IMD.
The Netherlands has a comprehensive surveillance 
system for IMD through linkage of statutory notifi-
cations received by the National Institute of Public 
Health and the Environment and laboratory data from 
the Netherlands Reference Laboratory for Bacterial 
Meningitis (NRLBM) (see [6] for more elaborate descrip-
tion). By means of this surveillance system compris-
ing epidemiological, clinical and microbiological data, 
we continuously monitor the situation concerning the 
increase of serogroup W IMD to evaluate whether addi-
tional measures need to be taken.
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Figure 3
Incidence of serogroup W invasive meningococcal disease 
by age group in the Netherlands, 2015–2017 (n = 139)
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